Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06838676 · ClinicalTrials.gov registry record · Phase 2
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
A Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06838676 is a Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 60 participants. The trial reports 20 study locations across 19 states.
The verdict
NCT06838676, a Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Conditions Studied
Interventions
- DRUG ACT001
Study Locations (20)
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Georgia
- Emory University/Children's Healthcare of Atlanta - Atlanta
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
Missouri
- St. Louis Children's Hospital - St Louis
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2035-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06838676
The ClinicalTrials.gov registry entry for NCT06838676 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Diffuse Intrinsic Pontine Gliomas (DIPG) appearing as the primary indexed condition, and to 1 intervention - of which ACT001 is the first listed.
NCT06838676 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Ohio, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06838676 about?
NCT06838676 is a clinical study titled "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas". This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
What is the current status of trial NCT06838676?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-07-10. Estimated completion is 2035-07.
What conditions does trial NCT06838676 study?
This clinical trial studies the following conditions: Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade Glioma.
What interventions are being tested in trial NCT06838676?
The interventions under investigation include: ACT001 (DRUG).
Who is sponsoring clinical trial NCT06838676?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06838676 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Intrinsic Pontine Gliomas (DIPG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.